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 Progression of Diabetes Retinal Status Within Community Screening Programs and 
Potential Implications for Screening Intervals 
 
Objective 
This study aimed to follow the natural progression of retinal changes in patients with diabetes. Such 
information should inform decisions with regard to the screening intervals for such patients. 
Research design and methods 
An observational study was undertaken linking the data from seven diabetes retinal screening programs across 
the U.K. for retinal grading results between 2005 and 2012. Patients with absent or background retinopathy 
were followed   up for progression to the end points referable retinopathy and treatable retinopathy 
(proliferative retinopathy). 
Results 
In total, 354,549 patients were observed for up to 4 years during which 16,196 patients progressed to referable 
retinopathy. Of patients with no retinopathy in either eye for two successive screening episodes at least 12 
months apart, the conditions of between 0.3% (95% CI 0.3–0.8%) and 1.3% (1.0–1.6%) of patients 
progressed to referable retinopathy, and rates of treatable eye disease were <0.3% at 2 years. The 
corresponding progression rates for patients with bilateral background retinopathy in successive screening 
episodes were 13–29% and up to 4%, respectively, in the different programs. 
 
Conclusions 
It may be possible to stratify patients for risk, according to baseline retinal criteria, into groups with low and 
high risk of their conditions progressing to proliferative retinopathy. Screening intervals for such diverse 
groups of patients could safely be modified according to their risk. 
 
About 5% of the U.K. population has received a diagnosis of diabetes, and the prevalence of both type 1 
diabetes and type 2 diabetes is increasing. The current recommendation in the U.K. is that patients with 
diabetes who are $12 years of age should have a retinal examination at least annually. Those patients found to 
have potentially sight-threatening diabetic retinopathy (defined as moderate nonproliferative disease or worse 
and/or diabetic macular edema) are referred to specialist ophthalmology clinics for further assessment and 
for treatment if required. 
Treatment with laser for proliferative disease and for clinically significant macular edema has been shown 
to reduce the risk of vision loss (1,2). More recently, intravitreal vascular endothelial growth factor therapy 
has been shown to improve vision in patients with diabetic macular edema (3–5). 
The rate of progression from no base-line retinopathy to referable diabetic eye disease has been shown to 
be ˂2% at 2 years (6,7), and lower for patients with newly diagnosed disease (8) and other defined groups (9). 
Retinal screening programs in Wales (n = 49,763) reported that in patients with type 2 diabetes and no 
baseline retinopathy, 1.2% were referred to an eye clinic over 4 years of follow-up (10). In an English 
regional program (n = 16,444), the rate was 1.3% over 5 years (11). In Scotland (n = 155,114), the rate was 
˂0.3% for patients who had 2 years of follow-up and had two successive screening episodes without 
retinopathy (12). A recent systematic review (13) has also suggested that screening every 2 years may be safe 
for patients with no base-line retinopathy. Comparisons among studies are difficult as study populations, 
screening criteria, imaging, and grading protocols vary. However, in summary, these studies appear to show 
that for patients with diabetes and without baseline retinopathy, the proportion who progress toward referable 
diabetic eye disease is ~0.5–0.6% at 2 years and ~1.2% at 4 years. 
Recent work showed that the conditions of patients with no diabetic retinopathy in either eye in each of 
two consecutive baseline sets of images progressed to sight-threatening diabetic retinopathy at an annual 
 rate of 0.7%, while that of patients with background retinopathy (BR) in one eye progressed at only 1.9% per 
year and that of those with background diabetic retinopathy in both eyes at baseline progressed at an annual 
rate of 11% (14). This risk stratification is useful in the U.K. screening programs because, unlike other risk 
estimation models proposed (15), it requires no clinical or demographic information. 
Within a multicenter retrospective cohort study, we aimed to estimate the rates of progression of 
diabetic retinopathy in people with diabetes under- going routine regular retinal screening and to explore the 
potential implications for optimal screening intervals for different risk groups. 
 
Research design and methods 
Seven diabetic retinal screening programs voluntarily contributed data to this study, including whole nation 
programs in Wales, Scotland, and Northern Ireland, and the following four English regional programs: 
Brighton, Derbyshire, Leeds, and Staffordshire. English programs were chosen from a reduced list of the 84 
English programs with a minimum of 10,000 screened patients in 2005, and a grading system that was not 
known to have given rise to any quality assurance concerns in the previous 5 years. Centers had a variety 
of geographical locations and differed according to their sociodemographic characteristics. 
A data set was defined comprising core demographic information for each anonymized patient linked 
with screening episode results. Data were sent by participating programs to Public Health England (originally 
Yorkshire and Humber Public Health Office), who cleaned and prepared the data for analysis. Arrangements 
were made for secure and confidential data transfer. Before commencing the study, we consulted with the 
chair of a research ethics committee who gave the opinion that because the data were fully anonymized there 
was no need for ethical review by a research ethics committee in England. Caldicott Guardian approval was 
given for use of the Scottish data. 
Criteria for data to be used in the analysis included having screening and grading results between 1 
January 2005 and 2012 (extraction dates between March and November); at least three grading episodes with 
fully graded images of both eyes; and the first two episodes with no referable diabetic retinopathy (NR). 
The grading protocols differed across the screening centers. The criteria for grading no retinopathy were no 
diabetes-related abnormality seen on the photograph. Referable retinopathy was defined as moderate 
nonproliferative diabetic retinopathy (NPDR) (equivalent to a National Health Service [NHS] Diabetic Eye 
Screening Programme [DESP] score R2 [preproliferative retinopathy]), venous beading, venous 
reduplication, intraretinal microvascular abnormality, multiple deep round or blot hemorrhages (Early 
Treatment of Diabetic Retinopathy Study [ETDRS] scale score 43–53), or proliferative retinopathy (ETDRS 
minimum scale score 61) in all centers. Referable maculopathy was defined as exudate within 1 disc diameter 
of the center of the fovea, circinate, or group of exudates within the macula or any microaneurysm or 
hemorrhage within 1 disc diameter of the center of the fovea, but only if associated with a best visual acuity 
of ˂0.3 logMAR (equivalent to Snellen test result of 6/12) for the centers in England. In the Scottish centers, 
referral maculopathy was defined as any blot hemorrhage or hard exudate within 1 disc diameter of the fovea. 
Referable diabetic eye disease was a composite term for referable retinopathy and referable 
maculopathy combined. Eyes disease requiring immediate treatment was termed “treatable diabetic eye 
disease” and comprised patients with proliferative retinopathy (ETDRS scale score $61). 
Patients were categorized according to baseline retinal findings of NR and then into nine ranked risk 
subgroups according to either the absence of any retinopathy in both eyes (i.e., NR) or the presence of BR 
(microaneurysms, retinal hemorrhages, any exudate, and ETDRS scale score 20–35) in one or both eyes 
in the first and second (“base-line”) screening episodes (14) (first episode/second episode). Risk levels were 
defined as follows: level 1 as BR in both eyes/BR; level 2 as BR in one eye/BR in both eyes; level 3 as NR in 
both eyes/BR in both eyes; level 4 as BR in both eyes/ BR in one eye; level 5 as BR in one eye/ BR in one 
eye; level 6 as NR/BR in one eye; level 7 as BR in both eyes/NR; level 8 as BR in one eye/NR; and level 9 
as NR/NR on both screening episodes. 
Analyses were based on electronic data from each of the seven centers. Screening data for each patient 
was recoded to assign a risk category using the results of the first two screening episodes after 1 January 
2005. For each patient, data from subsequent screening episodes was coded as an event or not, with an event 
 being the first screening episode with referable diabetic eye disease. Data were plotted using Kaplan- Meier 
estimates to show the cumulative percentage of patients in whom referable diabetic eye disease developed. In 
order to estimate the proportions of people with referable diabetic eye disease, we performed survival 
analysis, defining the time to event as the time from the baseline screening to the development of referable 
diabetic eye disease at a subsequent screening episode; hence, this was interval censored. Specifically, for 
those people in whom referable diabetic eye disease did not develop, the time to event was right censored 
at the date of the last screening, and for those people in whom referable diabetic eye disease developed, the 
data were left censored at the date of the last screening at which no referable diabetic eye disease was found 
and with event time at the date of the image set when referable diabetic eye disease was found. Estimates of 
the proportion of patients in whom referable diabetic eye had developed were obtained using log logistic 
parametric survival regression models with SAS Proc Lifereg. 
 
Results 
In total 354,549 patients were included from the seven centers across the U.K. There were 1,023,207 person-
years of observation (median 3 years, interquartile range 24–47 months). Patients were categorized into nine 
ranked risk sub-groups according to either the absence of any retinopathy or the presence of BR, 
(microaneurysms, retinal hemorrhages, any exudate, and ETDRS scale score 20–35) in one or both eyes over 
the two baseline screening episodes. The median number of screening episodes per person included was five 
(i.e., two baseline episodes and three follow-up episodes). 
The size of the seven programs varied from 19,358 to 138,077 patients with diabetes. The median ages 
varied from 60.8 to 63.9 years (37.8–48.0% were ˂60 years of age), with 41.9–44.5% being female and 5.9–
10.4% having type 1 diabetes. The median duration of diabetes varied from 2 to 4 years. 
Overall, there were 16,196 cases of referable retinopathy during the study follow-up period. The rate of 
progression of retinopathy was related to the baseline retinal findings (Fig. 1). Analysis was undertaken for 
three of nine possible risk groups. The risk groups were as follows: high risk (NHS DESP score R1/R1 [risk 
level 1]), medium risk (NHS DESP score R1/R0 [risk level 5]), and low risk (NHS DESP score R0/R0 [risk 
level 9]). The intermediary risk groups showed a step-wise change in risk, as expected, although in many 
regions, patients in risk category 6 showed a lower risk than expected, sometimes less than those in risk 
category 7. The rates of progression from no retinopathy to referable diabetic eye disease in high-risk, 
medium-risk, and low-risk groups at 1, 2, 3, and 4 years are shown in Tables 1, 2, and 3. There was a low rate 
of referable eye disease after 2 years in the low-risk group at 0.3–1.3%, and this steadily increased in the 
intermediate-risk group (2–9%) and higher-risk groups (13–29%). The rate of treatable disease was notably 
lower in all groups: ˂0.3% in the two lower-risk groups and 0.5–4.1% in the high-risk group. 
The Kaplan-Meier survival curves of progression to referable retinopathy for patients with high to 
moderate–risk and low-risk baseline retinopathy, are shown in Fig. 1. They show variation among the 
different programs. 
 
Conclusions 
The risk of future referral to ophthalmology for patients with no diabetic retinopathy at baseline after two 
screening episodes with no diabetic retinopathy was low, ranging from 0.4% to 1.3% at 2 years. In contrast, 
the risk of referable diabetic eye disease for patients with BR in both eyes at baseline was very high, ranging 
from 8% to 15% at 1 year. However, usually only patients with proliferative retinopathy require immediate 
treatment at the first visit to an ophthalmology clinic. In patients with no base-line retinopathy, all centers, 
except one, reported the development of proliferative retinopathy in ˂0.1% of patients at 2 years. The final 
center reported a rate at 0.27%. The comparable estimates at 3 years were 0.1–0.5%. For our high-risk group 
(those with mild NPDR in both eyes at two successive screening episodes), rates of the development of 
proliferative retinopathy were between 0.6% and 4.0% after 2 years, and be- tween 0.9% and 6.4% after 4 
years. After 2 years of follow-up, patients who had no retinopathy in either eye for two successive screening 
episodes appear to have a very low risk of the development of diabetic eye disease requiring immediate 
treatment, and rates requiring referral to an eye clinic that are well below the current annual referral rate of  
  
 
 
Figure 1—Progression to referable eye disease from mild NPDR or no retinopathy for the seven retinal screening 
programs. A: No diabetic retinopathy in each of two successive screenings. B: Mild NPDR in one eye at each of two 
successive screenings. C: Mild NPDR in both eyes on two successive screenings. 
 
~3% (16,17). 
This low-risk group of patients accounts for between one-half and two-thirds of patients within these 
U.K. retinal screening populations. These low referral rates are in keeping with those in previous 
observational studies (6–12), and they help to define the even lower rates of newly identified treatable 
disease. It would be possible to further refine the risk categories using additional predictive criteria (e.g., 
duration of diabetes, HbA1c level, blood pressure, and others). However, not all U.K. retinal screening 
programs currently have information on other clinical risk factors for retinopathy, so these cannot practically 
be used for risk stratification and could not be used for this study. 
The heterogeneity in results among these seven U.K. centers is an important finding, and may reflect 
screened populations with different age, sex, and ethnicity profiles, and glycemic and blood pressure control. 
It may also reflect differences in screening protocols, screening uptake, the completeness of the screening 
register, and the use of exclusion criteria. However, the variability may also reflect differences in grading. 
Different quality assurance procedures were used across the centers. The standardization of grading 
protocols and quality assurance may reduce the variation currently observed among centers. Masked 
standard image sets and automated grading could be used to enhance within program quality assurance 
processes. 
Screening for diabetic retinopathy was introduced at annual intervals for pragmatic and administrative 
reasons. However, there was no evidence base that this is the best screening interval. Modern computerized 
systems make variable screening intervals feasible. Since the pivotal Wisconsin Epidemiologic Study of 
Diabetic Retinopathy studies (18,19), the nature of diabetes care has changed, with earlier diagnosis; more 
young patients with type 2 diabetes; and lower targets for HbA1c levels, blood pressure, and cholesterol, 
all resulting in a lower prevalence of treatable diabetic eye disease (20,21) than in earlier years. In Iceland 
and parts of Sweden, low-risk individuals are currently screened every 2 to 3 years (9,22). These programs, 
however, are relatively small, and it is difficult to know how generalizable they are. For instance, in the 
Swedish study (9) only patients with type 2 diabetes were included and the mean Hba1c level was 6.4%, 
which is lower than in many regions. However, the accumulating evidence base indicates that screening at 
2-year or 3-year intervals for patients with no retinopathy on two consecutive occasions (i.e., a low-risk 
group) should be safe within a high-quality screening program. 
The proportion of patients progressing toward referable diabetic eye disease in our higher-risk 
categories ranged from 8% to 15% 1 year after baseline measurements and was much greater than in the 
lower-risk groups. It may be appropriate for these high-risk patients to be screened every 6 months. The 
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 proportion of patients in this high-risk group ranges from 2% to 7% and is much smaller than in the low-risk 
group. Implementing a variable screening interval for low-risk and high-risk patients is dependent on 
programs ensuring consistent, highly sensitive screening, with robust software allowing for accurate 
call/recall of patients. To maintain such standards, all programs would have to be part of a robust internal and 
external quality assurance scheme and education for the health-care staff involved. 
The main strengths of this study are its scale and the application of a robust method to explore the 
progression of diabetic retinopathy.  The results have implications for risk-based screening intervals.  A new 
data set was collated, leading to analyses that included ˃350,000 patients and ˃2 million screening intervals 
for a risk-stratified population (14). 
A criticism of this study is that it is based on retrospective, observational analysis and cannot directly 
show what the effects of changing screening intervals would be.  The ideal study would be a randomized, 
controlled trial comparing annual screening with risk-based screening intervals of 6-24 months.  If the 
difference in progression to proliferative or severe nonproliferactive disease between 1-year and 2-year 
intervals is ~0.5 per 1,000 patients, then to achieve 80% confidence of a noninferiority outcome with a 
censoring rate of 5% over 2 years, ˃120,000 patients would be required, making such a trial unlikely to be 
practical. Smaller-scale randomized studies looking at the impact on attendance, however, would be 
valuable. 
One concern about extending screening intervals is loss to follow-up, as it is known that missing one 
episode of retinal screening has been associated with an increased risk of subsequently requiring laser 
photocoagulation (23), which is estimated to be threefold higher (24). However, if patients are required to 
have documented absence of retinopathy at two consecutive baseline screenings over a given minimal 
interval (e.g., 12–24 months), then patients who are poorly compliant will be unlikely to achieve the 
criteria for categorization as low risk. Any change would need to be closely monitored for loss to follow-up, 
although other screening programs in the U.K. such as breast, cervical, and bowel cancer screening operate 
effectively at 2-year or 3-year intervals. 
The study included data from different grading centers. Although this might be seen as a weakness, in that 
we cannot guarantee uniformity in approach, it can also be seen as a strength; despite this potential 
variability, there were still consistent observations. This will make the findings more replicable in a “real-
world” setting. Our study demonstrates different risk categories based on base-line retinal appearances, but 
in the future it is possible that HbA1c level, type of diabetes, and time since diagnosis may further refine the 
risk categories. 
By reducing the screening interval to 2 years for low-risk groups, and increasing it to every 6 months for 
high-risk groups, there would be a reduction of 14–40% in screening episodes across the seven screening 
programs. This would be based on an expected referable rate of ~2.5%.  Extending the screening interval for 
some clearly identified low-risk patient groups may reduce the burden on patients and allow the 
redeployment of scarce health-care resources, such as investment in 6-month screening intervals for high-
risk patients and systems that encourage the attendance of patients who do not currently accept the offer of 
screening 
Further economic modeling is required to understand the overall impact on health-care system costs. 
The economic gains of longer screening intervals may be particularly important for poorer nations with 
burgeoning numbers of patients with newly diagnosed diabetes. 
The data from this study identify patients within diabetes retinal screening programs who are at low, 
medium, and high risk of progressing toward referable diabetic eye disease, and who need review within 
the ophthalmology department. This study supplies further evidence that it may be feasible and safe to move 
toward screening low-risk patients at intervals of 2 years, high-risk patients every 6 months, and intermediate-
risk patients annually. 
 
Proportion in whom 
proliferative retinopathy 
developed at 
1 year 0.76% (0.45 to 1.28%)    0.28% (0.01 to 5.22%)    0.24% (0.02 to 2.06%)     0.76% (0.05 to 4.65%)     0.66% (0.16 to 2.65%)    0.91% (0.19 to 3.24%)   2.42% (1.26 to 4.59%) 
2 year 1.25% (0.71 to 2.06%)    1.52% (0.13 to 8.32%)    0.56% (0.05 to 3.49%)    2.16% (0.33 to 7.53%) 2.3% (0.93 to 5.59%) 2.11% (1.11 to 4.2%) 3.98% (2.35 to 6.67%) 
3 year 1.77% (1.17 to 2.67%) 0.78% (0.17 to 3.85%)    2.99% (0.77 to 12.63%) 3.18% (1.84 to 6.02%)     5.45% (3.42 to 8.58%) 
4 year 2.65% (1.58 to 4.18%) 0.86% (0.19 to 3.85%) 4.68% (2.36 to 9.05%) 6.38% (4.18 to 11.76%) 
Cumulative proportion in 
whom referable retinopathy 
developed at 
1 year 13.2% (11.9 to 14.7%)     10.9% (8.2 to 14.5%) 8.3% (5 to 12.5%) 13.7% (9.1 to 18.5%) 13.1% (9.9 to 17.1%)     15.4% (12.6 to 18.6%) 11.3% (8.9 to 14.2%) 
2 year 21.4% (19.6 to 23.3%)     18% (11.8 to 26.5%) 13% (8.6 to 19.2%) 28.8% (21.8 to 34.8%)     22.4% (17.6 to 28.1%)   27.5% (23.2 to 32.3%)     19.5% (16.1 to 23.4%) 
3 year 28.7% (26.4 to 31%)     20.3% (15.3 to 34.9%)    16.1% (11.9 to 22.4%)     38.3% (31.6 to 45.5%)     26.7% (19.6 to 32.1%)    40.9% (36.9 to 45.1%)    26.3% (22.1 to 31.1%) 
4 year 35.4% (32.6 to 38.3%) 20.6% (15.1 to 27.4%)     41.5% (34.4 to 50.2%)     31.3% (22.4 to 38.8%)    46.3% (41.0 to 52.8%)    32.0% (24.7 to 40.6%) 
Mean length of follow-up 
after second baseline 
examination (years) 2.8 1.6 2.2 2.3 2.5 2.6 2.5 
Table 1—Expected cumulative proportion with referable diabetic eye disease from baseline BR in both eyes (level 1 high risk) at 1–4 years of follow-up (log logistic model) 
Program 
1 2 3 4 5 6 7 
Baseline DESP score R1/R1 in 
both eyes for 2 years (n at risk) 9,356 1,189 2,393 1,029 1,380 2,871 2,026 
Table 2—Expected proportion with referable diabetic eye disease from BR in one eye only (level 5 medium risk) at 1–4 years of follow-up (log logistic model) 
Program 
1 (n = 6,949) 2 (n = 1,343) 3 (n = 3,486) 4 (n =1,678) 5 (n = 851) 6 (n = 1,643) 7 (n = 729) 
Mean follow-up period (years) 3.1 1.6 2.4 2.7 2.6 3.0 2.6 
Progression to referable 
retinopathy at 
1 year 2.2% (1.5 to 3.1%) 1% (0.2 to 3.6%) 0.9% (0.1 to 5%) 5% (2.8 to 8.3%) 2.1% (0.7 to 6%) 2.5% (1.3 to 4.8%) 1.8% (0.4 to 7%) 
2 year 4.8% (3.6 to 6.5%) 1.5% (0.4 to 8%) 2.7% (0.6 to 8.7%) 9.1% (5.5 to 14%) 3.6% (0.9 to 9.4%) 5.2% (2.9 to 9.2%) 3.8% (1.5 to 9.6%) 
3 year 7.9% (5.9 to 10.6%) 3.7% (1.6 to 14.9%) 13.9% (10.1 to 19%) 5.8% (2.2 to 15.9%) 9.1% (5.7 to 14.3%) 5.4% (2.4 to 11.6%) 
4 year 11.9% (8.9 to 15.3%) 5.5% (1.9 to 19%) 17.7% (12.5 to 24.5%) 9.3% (3.2 to 22%) 11.7% (7.5 to 17.6%) 7.6% (2.7 to 48.7%) 
Progression to proliferative 
retinopathy at 
1 year 0.05% (0.01 to 0.45%) * * 0.28% (0.06 to 1.34%) 0.24% (0.09 to 0.65%) 0.06% (0 to 1.38%) ‡ 
2 year 0.18% (0.04 to 0.86%) 0.42% (0.12 to 1.49%) † 0.32% (0.05 to 2.12%) 
3 year 0.27% (0.07 to 1%) 0.56% (0.15 to 1.67%) 0.47% (0.09 to 2.33%) 
4 year 0.48% (0.13 to 1.75%) 0.6% (0.09 to 5.36%) 
*Only one patient progressed to NHS DESP score R3. †Two patients progressed to NHS DESP score R3. ‡No patients progressed to R3.
Progression to proliferative 
retinopathy at 
1 year 0.01% (0 to 0.05%) 0.01% (0 to 0.06%) * 0.02% (0 to 0.31%) 0.02% (0 to 0.13%) 0.04% (0.01 to 0.16%) 0.15% (0.07 to 0.35%) 
2 year 0.04% (0.01 to 0.12%) 0.05% (0.01 to 0.2%) 0.08% (0.01 to 0.43%) † 0.07% (0.02 to 0.27%) 0.27% (0.11 to 0.63%) 
3 year 0.08% (0.03 to 0.18%) 0.08% (0.01 to 0.25%) 0.12% (0.03 to 0.55%) 0.12% (0.04 to 0.33%) 0.39% (0.17 to 0.86%) 
4 year 0.14% (0.07 to 0.34%) 0.1% (0.03 to 0.29%) 0.13% (0.03 to 1.7%) 0.20% (0.08 to 0.46%) 0.5% (0.22 to 1.15%) 
*Only two patients progressed to NHS DESP score R3. †Four patients progressed to NHS DESP score R3.
Progression to referable 
disease at 
1 year 0.4% (0.3 to 0.5%) 0.1% (0.1 to 0.3%) 0.1% (0 to 0.4%) 0.6% (0.4 to 0.8%) 0.3% (0.2 to 0.5%) 0.5% (0.3 to 0.8%) 0.3% (0.2 to 0.5%) 
2 year 0.9% (0.7 to 1.1%) 0.4% (0.2 to 0.6%) 0.3% (0 to 0.8%) 1.3% (1 to 1.6%) 0.7% (0.4 to 1.1%) 1.1% (0.8 to 1.5%) 0.7% (0.5 to 1.1%) 
3 year 1.5% (1.2 to 1.8%) 0.5% (0.3 to 0.9%) 0.4% (0.2 to 2.9%) 2.2% (1.9 to 2.7%) 1.3% (0.7 to 2%) 2.4% (1.9 to 3.1%) 1.3% (0.9 to 2%) 
4 year 2.6% (2.1 to 3.2%) 1.1% (0.7 to 1.6%) 0.6% (0.2 to 2.9%) 3.3% (2.7 to 4%) 1.8% (0.9 to 3%) 3.6% (3 to 4.3%) 1.9% (1 to 3.4%) 
Table 3—Expected proportion with referable diabetic eye disease from no baseline retinopathy in either eye (level 9, low risk) at 1–4 years of follow-up (log logistic model) 
Program 
1 (n = 88,188) 2 (n = 63,619) 3 (n = 18,622) 4 (n = 23,146) 5 (n = 13,255) 6 (n = 23,482) 7 (n = 12,163) 
Mean follow-up 
period (years) 2.9 3.2 2.2 2.9 2.9 3.3 2.6 
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